Skip to content

Ascendis Pharma A/S

US · ASND #1127 by market cap Listed 2015
252.73 -3.23 -1.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 255.44 -0.20%
After-hours 252.73 0.00%
Overnight 256.05 +0.04%
277.18205.81252.732026-05-202026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ASND?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +9.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall D

The radar needs all six factors. Available grades are shown below.

Valuation D-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 34.7x Better than 17%
Forward P/E 37.6x Better than 12%
Price / Sales 14.5x Better than 7%
P/E vs own 5-yr range 94th pctl Better than 10%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 86.8% Better than 95%
Operating margin -18.9% Better than 13%
Net margin -31.7% Better than 10%
Return on equity -818.4% Better than 1%
Return on invested capital -71.6% Better than 4%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -0.2% Better than 73%
6-month return 2.3% Better than 60%
12-month return (ex latest month) 15.4% Better than 53%
Distance below 52-week high 10.4% Better than 82%
Financial Health D

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.0x Better than 21%
Debt to assets 66.9% Better than 6%
Interest coverage -1.6x Better than 21%
Free cash flow / net income 125.4% Better than 55%
Analyst View B

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 94.4% Better than 77%
Upside to average target 22.9% Better than 38%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -8.23%
1M +7.85%
3M -0.82%
6M +4.72%
YTD +18.52%
1Y +20.61%
3Y +169.55%
5Y +69.83%

Key statistics

Price & volume

Prev close
255.96
Open
255.44
Day range
251.55 - 256.65
Avg price
253.44
Volume
602.90K
Turnover
152.80M
Amplitude
1.99%
52-week range
188.08 - 282.15

Valuation

P/E
-61.28
P/E (TTM)
34.65
P/B
10.07
EPS
-4.12
Net profit
-271.37M
Net assets
1.65B

Share structure

Market cap
16.63B
Float cap
16.62B
Shares out
65.80M
Float shares
65.77M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2015-01-28
52-week range 69% of range
188.08 282.15

10.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-92.89M net over the window

Short interest

Shares short
3.00M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Ascendis Pharma A/S (ASND)?

Ascendis Pharma A/S last traded at 252.73. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Ascendis Pharma A/S's market cap?

About 16.63B.

What is the P/E ratio of Ascendis Pharma A/S?

The trailing twelve-month P/E is 34.65. The Valuation tab shows it against the stock's own five-year range.

Does Ascendis Pharma A/S pay a dividend?

Ascendis Pharma A/S does not currently pay a regular dividend.

Is Ascendis Pharma A/S a buy according to analysts?

The consensus of 18 analysts is a Buy rating, with an average 12-month price target of 310.69, which implies 22.9% upside from the current price. This is not investment advice.

What is Ascendis Pharma A/S's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Ascendis Pharma A/S a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Ascendis Pharma A/S discussion 0 comments

Add a comment